The Latest Cardiac and Vascular News
JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — Marizyme, Inc. (“Marizyme”, OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN) to advance the commercialization of Marizyme’s first-in-class FDA cleared product, DuraGraft™. DuraGraft™ was granted a De Novo – FDA Clearance on October 4, 2023, from the U.S. […]
JUPITER, FL, Oct. 23, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Marizyme, Inc. (“Marizyme” or the “Company”) (OTCQB: MRZM), today provided the following business update to the stockholders and the investing public from the Company’s Chief Executive Officer, David Barthel: “I am very pleased to bring you an update on […]
JUPITER, FL, Oct. 06, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Marizyme, Inc. (OTCQB:MRZM) (“Marizyme” or the “Company”), a global medical technology company focused on the development of products to address unmet clinical needs, today announced that it was granted a de novo from the U.S. Food and Drug Administration (FDA) for its […]
JUPITER, Fla., March 31, 2021 /PRNewswire/ — Marizyme, Inc. (OTCQB: MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, and other surgical indications, announces that Board Chairman James Sapirstein has issued a Letter to Shareholders providing a business update for the Company’s recent activities. The […]
JUPITER, Fla., March 4, 2021 /PRNewswire/ — Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has entered into a supply and distribution agreement with Abdera Financial, Inc., a Chilean based distributor, […]
Company Focuses on Commercial Development, Revenue Generation and Operating Excellence JUPITER, Fla., Feb. 1, 2021 /PRNewswire/ — Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that it has added two life science industry […]
Latest Approval Joins a Growing List of Countries for Commercial Sales in 2021 JUPITER, Fla., Jan. 14, 2021 /PRNewswire/ — Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that its flagship product DuraGraft® is […]
DuraGraft is a one-time intraoperative treatment used during vascular surgery to reduce the incidence of complications associated with graft failure JUPITER, Fla., Jan. 11, 2021 /PRNewswire/ — Marizyme, Inc. (OTCQB: MRZM), a global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, today announced […]
Steven Brooks, M.D., MBA, FACC – Appointed EVP of Medical and Regulatory Affairs, Chief Medical Officer Donald Very, Ph.D. – Appointed EVP, Research & Development William Hearl, Ph.D. – Named Independent Member of Board of Directors JUPITER, Fla., Dec. 4, 2020 /PRNewswire/ — Marizyme, Inc. (OTCQB: MRZM), a publicly traded global biotechnology company developing products […]
New York, Sept. 29, 2020 (GLOBE NEWSWIRE) — Univest Securities, LLC, a member of FINRA and SIPC, is a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing for the acquisition of Somulation, Inc. by its client Marizyme, Inc. (OTC:MRZM) (“Marizyme” or the “Company”), […]
